Industry Profile: India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 percent of global demand for various vaccines, 40 percent of the generic market in the US, and 25 percent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Over 80 percent of the antiretroviral drugs used globally to combat AIDS (Acquired Immuno Deficiency Syndrome) are supplied by Indian pharmaceutical firms. The pharmaceutical sector was valued at US$ 33 billion in 2017. The country’s pharmaceutical industry is expected to expand at a CAGR of 22.4 percent over 2015–20 to reach US$ 55 billion. India’s pharmaceutical exports stood at US$ 17.27 billion in 2017-18 and are expected to reach US$ 20 billion by 2020. Indian companies received 304 Abbreviated New Drug Application (ANDA) approvals from the US Food and Drug Administration (USFDA) in 2017. The country accounts for around 30 percent (by volume) and about 10 percent (value) in the US$ 70-80 billion US generics market. India’s biotechnology industry comprising bio-pharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics is expected to grow at an average growth rate of around 30 percent a year and reach US$ 100 billion by 2025. Biopharma, comprising vaccines, therapeutics, and diagnostics, is the largest sub-sector contributing nearly 62 percent of the total revenues at Rs 12,600 crore (US$ 1.89 billion).
Company profile: Though the company is new, it concentrates on CNS and grows in an organic-inorganic way. The company was established in 2007. The company is focusing on some lesser competitive segments like chronic illness medicine. It is a 62.4% contributor, A large part of which is CNS. Eris is the second-fastest-growing company in Chronic therapy among the top 25 companies. The company has focused on therapeutic areas treated by a super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, and Gastroenterologists. Super specialists and specialists contribute 92.6% of its revenue. The remaining is Generic. The company has an average prescriber base of 80,267 doctors for Fiscal 2018, per the IMS medical audit.
Shareholding pattern: BSE Data
Financials and ratios : [table id=164 /]
Future prospectus: The company is focusing on consolidation after four acquisitions in one year, including the latest buyout of the Indian business of Strides Shasun Ltd. With the Rs500 crore acquisition of Stride’s domestic formulations business, Eris will be among the top 10 companies in the central nervous system (CNS) drugs segment in the country.
